|
Characteristics
|
No.
|
OS
|
RFS
|
|---|
|
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
|---|
|
Univariate analysis
|
|
nIL4Rα/nIL13Rα1, −/−
|
31/89
|
1
|
< 0.001
|
1
|
< 0.001
|
|
+/−
|
13/89
|
3.230 (0.640–16.303)
|
0.156
|
2.990 (1.048–8.535)
|
0.041
|
|
−/+
|
9/89
|
7.673 (1.916–30.738)
|
0.004
|
7.670 (2.770–21.237)
|
< 0.001
|
|
+/+
|
36/89
|
18.871 (5.553–64.130)
|
< 0.001
|
10.815 (4.648–25.169)
|
< 0.001
|
|
nIL4Rα/nIL13Rα1, −/−
|
31/89
|
1
|
< 0.001
|
1
|
< 0.001
|
|
+/− or −/+
|
22/89
|
5.355 (1.434–20.004)
|
0.013
|
4.424 (1.801–10.871)
|
0.001
|
|
+/+
|
36/89
|
19.504 (5.671–67.080)
|
< 0.001
|
10.791 (4.633–25.134)
|
< 0.001
|
|
Multivariate analysis Model 1
|
|
Distant metastasis, presence (vs. absence)
| |
3.743 (1.762–7.952)
|
< 0.001
|
2.083 (1.127–3.849)
|
0.019
|
|
nIL4Rα/nIL13Rα1, −/−
| |
1
|
< 0.001
|
1
|
< 0.001
|
|
+/−
| |
3.140 (0.626–15.760)
|
0.165
|
2.972 (1.041–8.486)
|
0.042
|
|
−/+
| |
2.808 (0.610–12.924)
|
0.185
|
4.827 (1.601–14.551)
|
0.005
|
|
+/+
| |
11.927 (3.359–42.353)
|
< 0.001
|
8.729 (3.628–21.003)
|
< 0.001
|
|
Multivariate analysis Model 2
|
|
Distant metastasis, presence (vs. absence)
| |
3.663 (1.836–7.307)
|
< 0.001
|
2.312 (1.305–4.095)
|
0.004
|
|
nIL4Rα/nIL13Rα1, −/−
| |
1
|
< 0.001
|
1
|
< 0.001
|
|
+/− or −/+
| |
2.947 (0.750–11.584)
|
0.122
|
3.619 (1.447–9.052)
|
0.006
|
|
+/+
| |
12.004 (3.396–42.433)
|
< 0.001
|
8.397 (3.491–20.197)
|
< 0.001
|
- Abbreviations: OS Overall survival, RFS Relapse-free survival, HR Hazard ratio, 95% CI 95% confidence interval, nIL4Rα Nuclear expression of IL4Rα, cIL4Rα; nIL13Rα1 Nuclear expression of IL13Rα1
